United Laboratories International Holdings (3933) Stock Overview
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
3933 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
The United Laboratories International Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$10.09 |
| 52 Week High | HK$17.98 |
| 52 Week Low | HK$9.46 |
| Beta | 0.39 |
| 1 Month Change | -22.80% |
| 3 Month Change | -15.64% |
| 1 Year Change | -19.28% |
| 3 Year Change | 75.48% |
| 5 Year Change | 65.41% |
| Change since IPO | 179.50% |
Recent News & Updates
Recent updates
The United Laboratories International Holdings Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 27
The United Laboratories International Holdings Limited (HKG:3933) Looks Inexpensive But Perhaps Not Attractive Enough
Feb 09Little Excitement Around The United Laboratories International Holdings Limited's (HKG:3933) Earnings
Oct 28United Laboratories International Holdings' (HKG:3933) Profits May Not Reveal Underlying Issues
Oct 06United Laboratories International Holdings (HKG:3933) Has Affirmed Its Dividend Of CN¥0.438
Jun 30Optimistic Investors Push The United Laboratories International Holdings Limited (HKG:3933) Shares Up 25% But Growth Is Lacking
Jun 11United Laboratories International Holdings (HKG:3933) Has A Pretty Healthy Balance Sheet
Apr 23Earnings Miss: The United Laboratories International Holdings Limited Missed EPS By 9.8% And Analysts Are Revising Their Forecasts
Mar 28What The United Laboratories International Holdings Limited's (HKG:3933) 26% Share Price Gain Is Not Telling You
Mar 24Benign Growth For The United Laboratories International Holdings Limited (HKG:3933) Underpins Its Share Price
Feb 05Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching
Jan 10These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Nov 11The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market
Oct 23Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching
Aug 30Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified
Feb 29The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement
Jan 04United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt
Dec 14With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case
Nov 26Is United Laboratories International Holdings (HKG:3933) A Risky Investment?
Aug 31Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?
Aug 10United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet
Dec 23Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?
Oct 19Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?
Aug 30Shareholder Returns
| 3933 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.3% | -2.1% | 1.8% |
| 1Y | -19.3% | 55.2% | 28.2% |
Return vs Industry: 3933 underperformed the Hong Kong Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: 3933 underperformed the Hong Kong Market which returned 28.2% over the past year.
Price Volatility
| 3933 volatility | |
|---|---|
| 3933 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 3933 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3933's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 18,000 | n/a | www.tul.com.cn |
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules.
The United Laboratories International Holdings Limited Fundamentals Summary
| 3933 fundamental statistics | |
|---|---|
| Market cap | HK$20.04b |
| Earnings (TTM) | HK$2.39b |
| Revenue (TTM) | HK$15.15b |
Is 3933 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3933 income statement (TTM) | |
|---|---|
| Revenue | CN¥13.21b |
| Cost of Revenue | CN¥7.70b |
| Gross Profit | CN¥5.51b |
| Other Expenses | CN¥3.43b |
| Earnings | CN¥2.09b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.06 |
| Gross Margin | 41.74% |
| Net Profit Margin | 15.79% |
| Debt/Equity Ratio | 28.5% |
How did 3933 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 09:26 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The United Laboratories International Holdings Limited is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Shao | BofA Global Research |
| Yue-Kwong Lui | CGS International |
| Jing Qiang | China International Capital Corporation Limited |